Tarsus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Tarsus Pharmaceuticals

27/02/2024 14:32

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of $1.31​​ per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of -49 cents.  The mean expectation of
nine analysts for the quarter was for a loss of $1.36 per share.
Wall Street expected results to range from $-1.72 to $-1.08 per
share.
    * Revenue rose 30.8% to $13.08 million from a year ago;
analysts
expected $5.67 million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.31​.
    * The company reported a quarterly loss of $41.9 million.
    * Tarsus Pharmaceuticals Inc shares had risen by 63.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $50.00 

This summary was machine generated from LSEG data February 27 at
02:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.36          -1.31          Beat
 Sep. 30 2023      -1.37          -1.28          Beat
 Jun. 30 2023      -1.08          -1.17          Missed
 Mar. 31 2023      -0.94          -0.88          Beat